Download PDF
Thromb Haemost 2020; 120(08): 1159-1165
DOI: 10.1055/s-0040-1713636
Review Article

The Effect of Age on von Willebrand Factor and Bleeding Symptoms in von Willebrand Disease

Craig D. Seaman
1   Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
2   Hemophilia Center of Western Pennsylvania, Pittsburgh, Pennsylvania, United States
,
Margaret V. Ragni 
1   Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
2   Hemophilia Center of Western Pennsylvania, Pittsburgh, Pennsylvania, United States
› Author Affiliations Funding This study was funded by the University of Pittsburgh Cancer Institute.
› Further Information
   Permissions and Reprints

Abstract

von Willebrand disease (VWD) is a quantitative or qualitative defect in von Willebrand factor (VWF) resulting in mucocutaneous bleeding symptoms and hemorrhage following hemostatic challenges, such as trauma or surgery. VWD-specific therapy, DDAVP (1-desamino-8-D-arginine vasopressin) and VWF concentrates, is necessary periprocedurally to ensure adequate hemostasis. The aging VWD patient may complicate this matter. The plasma concentration of many coagulation proteins, including VWF, increases with age. While it has been established that VWF levels increase with age in a healthy population, emerging research demonstrates this occurs in certain subtypes of VWD, too. Thus, the management of periprocedural VWD-specific therapy in the aging VWD patient is problematic when VWF levels increase over time to normal, and hematologists are left with uncertainty regarding whether or not periprocedural VWD-specific therapy is still necessary. In this article, we will review the current state of the literature regarding the effect of age on VWF levels in the healthy population and VWD while exploring possible etiologies for this phenomenon. Further, we will detail how this affects bleeding symptoms and highlight what research remains to be done to optimize care in this patient population.

Keywords

von Willebrand disease - von Willebrand factor - age - bleeding score

Authors' Contributions

C.D.S. and M.V.R. researched the topic, analyzed the data, formulated the conclusions, and wrote the paper.




Publication History

Received: 17 April 2020

Accepted: 15 May 2020

Article published online:
06 July 2020

Georg Thieme Verlag KG
Stuttgart · New York

 

  • References

  • 1 Lillicrap D. von Willebrand disease: advances in pathogenetic understanding, diagnosis, and therapy. Blood 2013; 122 (23) 3735-3740
    CrossrefPubMedGoogle Scholar
  • 2 Leebeek FWG, Eikenboom JCJ. von Willebrand's disease. N Engl J Med 2016; 375 (21) 2067-2080
    CrossrefPubMedGoogle Scholar
  • 3 Tosetto A, Castaman G, Rodeghiero F. Bleeding scores in inherited bleeding disorders: clinical or research tools?. Haemophilia 2008; 14 (03) 415-422
    CrossrefPubMedGoogle Scholar
  • 4 World Federation of Hemophilia. Compendium of assessment tools. Available at: https://elearning.wfh.org/resource/compendium-of-assessment-tools/#bleeding_assessment_tools1a42-60ce78a1-2573f205-9a34 . Accessed May 10, 2020
    PubMedGoogle Scholar
  • 5 Nichols WL. The Diagnosis, Evaluation, and Management of von Willebrand Disease. Bethesda, MD: National Heart, Lung, and Blood Institute; 2007. . NIH Pub. No. 08–5832
    Google Scholar
  • 6 Favaloro EJ, Franchini M, Lippi G. Aging hemostasis: changes to laboratory markers of hemostasis as we age - a narrative review. Semin Thromb Hemost 2014; 40 (06) 621-633
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Kawecki C, Lenting PJ, Denis CV. von Willebrand factor and inflammation. J Thromb Haemost 2017; 15 (07) 1285-1294
    CrossrefPubMedGoogle Scholar
  • 8 Coppola R, Mari D, Lattuada A, Franceschi C. von Willebrand factor in Italian centenarians. Haematologica 2003; 88 (01) 39-43
    PubMedGoogle Scholar
  • 9 Kadir RA, Economides DL, Sabin CA, Owens D, Lee CA. Variations in coagulation factors in women: effects of age, ethnicity, menstrual cycle and combined oral contraceptive. Thromb Haemost 1999; 82 (05) 1456-1461
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Albánez S, Ogiwara K, Michels A. , et al. Aging and ABO blood type influence von Willebrand factor and factor VIII levels through interrelated mechanisms. J Thromb Haemost 2016; 14 (05) 953-963
    CrossrefPubMedGoogle Scholar
  • 11 Higgins RA, Goodwin AJ. Automated assays for von Willebrand factor activity. Am J Hematol 2019; 94 (04) 496-503
    CrossrefPubMedGoogle Scholar
  • 12 Rydz N, Grabell J, Lillicrap D, James PD. Changes in von Willebrand factor level and von Willebrand activity with age in type 1 von Willebrand disease. Haemophilia 2015; 21 (05) 636-641
    CrossrefPubMedGoogle Scholar
  • 13 Abou-Ismail MY, Ogunbayo GO, Secic M, Kouides PA. Outgrowing the laboratory diagnosis of type 1 von Willebrand disease: a two decade study. Am J Hematol 2018; 93 (02) 232-237
    CrossrefPubMedGoogle Scholar
  • 14 Borghi M, Guglielmini G, Mezzasoma AM. , et al. Increase of von Willebrand factor with aging in type 1 von Willebrand disease: fact or fiction?. Haematologica 2017; 102 (11) e431-e433
    CrossrefPubMedGoogle Scholar
  • 15 Sanders YV, Giezenaar MA, Laros-van Gorkom BA. , et al; WiN study group. von Willebrand disease and aging: an evolving phenotype. J Thromb Haemost 2014; 12 (07) 1066-1075
    CrossrefPubMedGoogle Scholar
  • 16 Flood VH, Christopherson PA, Gill JC. , et al. Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States. Blood 2016; 127 (20) 2481-2488
    CrossrefPubMedGoogle Scholar
  • 17 Atiq F, Meijer K, Eikenboom J. , et al; WiN study group. Comorbidities associated with higher von Willebrand factor (VWF) levels may explain the age-related increase of VWF in von Willebrand disease. Br J Haematol 2018; 182 (01) 93-105
    CrossrefPubMedGoogle Scholar
  • 18 James PD, Notley C, Hegadorn C. , et al. The mutational spectrum of type 1 von Willebrand disease: results from a Canadian cohort study. Blood 2007; 109 (01) 145-154
    CrossrefPubMedGoogle Scholar
  • 19 Goodeve A, Eikenboom J, Castaman G. , et al. Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD). Blood 2007; 109 (01) 112-121
    CrossrefPubMedGoogle Scholar
  • 20 Swystun LL, Lillicrap D. Genetic regulation of plasma von Willebrand factor levels in health and disease. J Thromb Haemost 2018; 16 (12) 2375-2390
    CrossrefPubMedGoogle Scholar
  • 21 Miesbach W, Berntorp E. When von Willebrand disease comes into age - a matter of change?. Eur J Haematol 2011; 86 (06) 496-501
    CrossrefPubMedGoogle Scholar
  • 22 Tosetto A, Rodeghiero F, Castaman G. , et al. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost 2006; 4 (04) 766-773
    CrossrefPubMedGoogle Scholar
  • 23 de Wee EM, Sanders YV, Mauser-Bunschoten EP. , et al; WiN study group. Determinants of bleeding phenotype in adult patients with moderate or severe von Willebrand disease. Thromb Haemost 2012; 108 (04) 683-692
    Article in Thieme ConnectPubMedGoogle Scholar
  • 24 Bowman M, Mundell G, Grabell J. , et al. Generation and validation of the Condensed MCMDM-1VWD Bleeding Questionnaire for von Willebrand disease. J Thromb Haemost 2008; 6 (12) 2062-2066
    CrossrefPubMedGoogle Scholar
  • 25 Seaman CD, Ragni MV. The association of aging with von Willebrand factor levels and bleeding risk in type 1 von Willebrand disease. Clin Appl Thromb Hemost 2018; 24 (03) 434-438
    CrossrefPubMedGoogle Scholar